bioAffinity Technologies (Nasdaq: BIAF) is meeting rising demand for its noninvasive lung cancer test, CyPath® Lung, through a strategic logistics partnership with Cardinal Health™ OptiFreight®. Leveraging real-time shipping analytics and national reach, the collaboration ensures timely delivery of critical sputum samples—supporting CyPath® Lung’s continued U.S. expansion, including access for rural veterans through the Federal Supply Schedule.

Connect Biopharma (Nasdaq: CNTB) will present new clinical data for its next-gen IL-4Rα antibody, rademikibart, at the European Academy of Allergy and Clinical Immunology Annual Congress (EAACI) 2025, highlighting its ability to reduce exacerbations and rapidly improve lung function in eosinophilic Type 2 asthma. With peak sales potential projected at over $5 billion across asthma and COPD, rademikibart is emerging as a differentiated contender in respiratory biologics, backed by strong Phase 2 results and rapid onset of action.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has launched a new 8-count bottle of ARAKODA® (tafenoquine), the only weekly malaria prophylactic covering both blood and liver stages. Tailored for short-term travelers, the format is now available via major retail pharmacies—enhancing convenience and expanding access to a key preventative solution for global travelers.

Calidi Biotherapeutics (NYSE American: CLDI) unveiled new preclinical data at ASCO 2025 for CLD-401, its lead RedTail platform candidate, engineered with a CD55-enhanced envelope for immune evasion and systemic delivery. Featuring an IL-15 superagonist payload to amplify antitumor immunity, the platform aims to revolutionize treatment of metastatic cancers via intravenous administration—a major leap forward in systemic oncolytic immunotherapy.